Abstract
Since its inception, the Journal for Immunotherapy of Cancer (JITC) has focused on all aspects of tumor immunology and cancer immunotherapy from bench to bedside. Clinical advances in immuno-oncology are accelerating, with an increasing number of approved drugs that specifically target the immune
Highlights
Since its inception, the Journal for Immunotherapy of Cancer (JITC) has focused on all aspects of tumor immunology and cancer immunotherapy from bench to bedside
Given the explosion of interest and clinical activity in cancer immunotherapy, we are pleased to launch a new section of JITC, the Clinical Trials Monitor, edited by Leisha A
The section aims to address trial design and analysis considerations that may be unique to cancer immunotherapy, and to provide guidance for implementing and managing the use of cancer immunotherapies in the clinic
Summary
The Journal for Immunotherapy of Cancer (JITC) has focused on all aspects of tumor immunology and cancer immunotherapy from bench to bedside. Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer Clinical advances in immuno-oncology are accelerating, with an increasing number of approved drugs that target the immune system to treat cancer.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
